Evidence map›Paper›PMID 40175696›Full record

ArticleUpdates in surgery2025

Genetic predictors of postoperative recurrence in node-negative intrahepatic cholangiocarcinoma.

Bo Zhang, Xiang-Yu Wang, Lu-Yu Yang, Xiao-Tian Shen, Ying Zhu, Wen-Wei Zhu, Jie Fan, Lu Lu, Jin-Hong Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bo Zhang *Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China.
Xiang-Yu Wang *Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China.
Lu-Yu Yang *Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China.
Xiao-Tian ShenHepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China.
Ying ZhuHepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China.
Wen-Wei ZhuHepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China.
Jie FanDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Lu LuHepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China. lulu@huashan.org.cn.
Jin-Hong ChenHepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China. jinhongch@hotmail.com.ORCID http://orcid.org/0000-0003-0952-9990

Funding

National Natural Science Foundation of China 82203792Program of Shanghai Academic/Technology Research Leader 22XD1400300
6 · The paper itself

Abstract

Recent studies have revealed the prognostic value of genetic alterations in intrahepatic cholangiocarcinoma (ICC). However, the influence of individual mutations on postoperative recurrence has not been comprehensively evaluated, especially for lymph node-negative cases. A total of 589 localized ICCs with clinically or pathologically negative lymph node (cN0M0 or pN0M0) from 3 independent cohorts were included. The impact of clinicopathological and mutational parameters on recurrence-free survival (RFS) and post-recurrence survival (PRS) was analyzed using the Cox proportional hazards model. The effect of prognostic mutations on RFS and PRS was estimated by Kaplan-Meier analysis. Extremes of survivorship analysis was used to reveal distinct genomic profiles between cases with very early recurrence (VER) and long-term no recurrence (LNR). Among the recurrent mutations, only TP53 and KRAS showed significant association with RFS in both of the two screening cohorts. In the validation cohort, TP53 and KRAS mutations were both independent predictors for shorter RFS. Compared with wild-type patients, TP53 and KRAS mutations were more frequently observed in VER group than in LNR group, and were more enriched in patients with intrahepatic and extra-hepatic recurrence (IER). Furthermore, TP53 mutation was significantly associated with worse survival and lower probability of repeated hepatectomy in patients suffered from recurrence. TP53 and KRAS mutations were important genetic predictors that correlated with earlier and more aggressive recurrence in node-negative ICC patients after surgery. Effective peri-operative therapies for these high-risk tumor biology are needed to improve the clinical outcome for related patients.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaNeoplasm Recurrence, LocalProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53AgedFemaleHepatectomyHumansMaleMiddle AgedMutationPrognosisKRAS protein, humanProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53Gene mutationHepatectomyIntrahepatic cholangiocarcinomaPrognosisRecurrence

Identifiers

PMID40175696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.